Securities suits claim Inovio Pharmaceuticals hid CELLECTRA defects, BLA filing delayed

Central Allegation: CELLECTRA Deficiencies and Delayed BLA

Multiple plaintiff firms allege Inovio Pharmaceuticals faces a coordinated wave of securities litigation tied to manufacturing problems with its CELLECTRA device and overstated regulatory prospects for its lead candidate, INO‑3107. Complaints filed and notices circulated over the past 72 hours claim the company concealed deficiencies in CELLECTRA production that make a Biologics License Application (BLA) filing in the second half of 2024 unlikely and undermine assertions that INO‑3107 is eligible for FDA accelerated approval or priority review. The suits describe INO‑3107 as a DNA‑based therapy for recurrent respiratory papillomatosis (RRP) that relies on Inovio’s plasmids plus the CELLECTRA delivery system, and say public statements about regulatory timelines and commercial readiness are materially misleading.

Plaintiffs outline five core allegations: deficient device manufacturing, improbability of the H2 2024 BLA submission, insufficient evidentiary basis for accelerated approval or priority review, overstated regulatory and commercial prospects, and that public statements were therefore false or misleading. Lead complaints allege these misrepresentations caused investor losses when the market learned contrary facts. One filing — brought by Pomerantz LLP in the U.S. District Court for the Eastern District of Pennsylvania (docket no. 26‑cv‑00803) — and parallel notices from firms including Gross, Schall, DJS and Rosen emphasize the same operational and regulatory shortcomings rather than focusing on market or price movements.

The companies’ DNA medicines description and the role of CELLECTRA in facilitating cellular uptake of plasmids figure centrally in pleadings, which assert investors were led to believe Inovio was transitioning to a commercial‑stage company with a near‑term regulatory path. Defendants in the complaints are accused of making repeated public assurances about regulatory milestones and commercial prospects without adequate manufacturing controls or supporting data. The cases remain at early stages; class certification, discovery and any remedies will determine whether the allegations translate into liability.

Broad Counsel Outreach to Shareholders

Several national and international plaintiff firms are actively soliciting potential class members and lead‑plaintiff candidates, providing loss‑submission portals and offering contingency representation. Firms explicitly note attorney‑advertising caveats and warn prior results do not guarantee outcomes.

Lead‑Plaintiff Deadline and Participation Details

All notices identify the class period as Oct. 10, 2023 through Dec. 26, 2025 and set an April 7, 2026 deadline for motions to be appointed lead plaintiff; potential claimants are told participation is voluntary and that absent action they remain absent class members. Contact and registration mechanisms are provided by each firm.